Truist analyst Asthika Goonewardene downgraded TCR2 Therapeutics (TCRR) to Hold from Buy after the company entered into a definitive merger agreement under which Adaptimmune (ADAP) will combine with TCR2 in an all-stock transaction.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRR:
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Craters after Acquiring TCRR
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
- Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction